Sandoz Group AG (Sandoz Group AG) Change In Receivables : $-302 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Change In Receivables?

Sandoz Group AG's change in receivables for the quarter that ended in Dec. 2023 was $-302 Mil. It means Sandoz Group AG's Accounts Receivable increased by $302 Mil from Dec. 2022 to Dec. 2023 .

Sandoz Group AG's change in receivables for the fiscal year that ended in Dec. 2023 was $-302 Mil. It means Sandoz Group AG's Accounts Receivable increased by $302 Mil from Dec. 2022 to Dec. 2023 .

Sandoz Group AG's Accounts Receivable for the quarter that ended in Dec. 2023 was $2,615 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Sandoz Group AG's Days Sales Outstanding for the three months ended in Dec. 2023 was 23.91.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sandoz Group AG's liquidation value for the three months ended in Dec. 2023 was $-6,356 Mil.

Sandoz Group AG Change In Receivables Historical Data

The historical data trend for Sandoz Group AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Change In Receivables Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Change In Receivables

-178.00

-302.00

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Change In Receivables	-178.00	-302.00

Sandoz Group AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-302 Mil.

Sandoz Group AG (OTCPK:SDZNY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sandoz Group AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2615	/	9979	*	91
=	23.91

2. In Ben Graham's calculation of liquidation value, Sandoz Group AG's accounts receivable are only considered to be worth 75% of book value:

Sandoz Group AG's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1109	-	10776	+	0.75 * 2615	+	0.5 * 2700
=	-6,356

Sandoz Group AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024